WorldFuture and humanity

First Patient Dosed in Australia in ATG-101 First-in-Human Trial
Antigene Corporation

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced dosing in Australia of the first subject in the Phase I PROBE
3 min read